Results 131 to 140 of about 7,568,653 (278)
Diagnosis of Portal Hypertension: Advancing Towards Non‐Invasive Solutions
This review systematically summarizes a full spectrum of non‐invasive diagnostic approaches for portal hypertension (PH), including imaging modalities, elastography, serum biomarkers, composite scoring systems and endoscopic ultrasound‐guided portal pressure gradient (EUS‐PPG), and analyzes their performance across different liver disease etiologies ...
Lijia Yin, Huikuan Chu, Ling Yang
wiley +1 more source
Nonalcoholic fatty liver disease (NAFLD), among the most common chronic liver diseases worldwide, affects approximately 25% of the global population. Its incidence is increasing owing to various risk factors, including genetic variation, metabolic health,
Chia-Chien Kang +6 more
doaj +1 more source
ABSTRACT Metabolic dysfunction‐associated fatty liver disease (MAFLD) lacks effective pharmacological therapies and is strongly associated with excessive fructose consumption. Ferroptosis and autophagy dysregulation are increasingly recognized as key drivers of MAFLD progression.
Puyu Zhang +11 more
wiley +1 more source
Hyperoside ameliorates metabolic dysfunction in high‐fat diet‐induced type 2 diabetic mice, accompanied by enhanced brown adipose tissue thermogenic activity, inguinal white adipose tissue browning‐related changes, reduced M1 macrophage polarization, and gut microbiota remodeling.
WeiFeng Cai +7 more
wiley +1 more source
Magnoflorine ameliorates metabolic dysfunction‐associated steatohepatitis by promoting AMPKα‐mediated lipophagy and fatty acid oxidation. ABSTRACT Emerging as a significant clinical burden, metabolic dysfunction‐associated steatohepatitis (MASH) continues to challenge global healthcare systems due to limited effective interventions.
Zhengjie Lu +6 more
wiley +1 more source
In this systematic review and meta‐analysis of four randomized controlled trials (n = 178) of Iranian propolis in adults with MASLD, propolis supplementation was associated with improvement in ultrasound‐assessed hepatic steatosis (three trials, n = 156; RR 2.41, 95% CI 1.59–3.66) and a modest reduction in fasting glucose, with no significant effects ...
Ting‐An Kuo +4 more
wiley +1 more source
Redefining Fatty Liver Disease: How Updated Nomenclature Reshapes Clinical Laboratory Diagnostics
The nomenclature of fatty liver disease has undergone substantial evolution, transitioning from nonalcoholic fatty liver disease to metabolic‐associated fatty liver disease, and more recently to metabolic dysfunction‐associated steatotic liver disease ...
Ran Wei +3 more
doaj +1 more source
Autophagy: a new target for nonalcoholic fatty liver disease therapy
Yuqing Mao,1 Fujun Yu,1 Jianbo Wang,2 Chuanyong Guo,3 Xiaoming Fan1 1Department of Gastroenterology and Hepatology, Jinshan Hospital of Fudan University, Shanghai, 2Department of Gastroenterology and Hepatology, The Central Hospital of Lishui City ...
Mao YQ, Yu FJ, Wang JB, Guo CY, Fan XM
core
The graphical abstract provides a schematic overview of the main topics covered in this review, including lipid metabolism dysfunction in MASLD, the potential regulatory effects of natural bioactive compounds, and the challenges associated with their clinical translation.
Ji‐Kai Ma +7 more
wiley +1 more source

